Bcl-2 expression is correlated with a low apoptotoci index and associated with progesterone receptor immunoreactivity in endometrial carcinomas

Journal of Pathology

Volumn 180, Issue 3, 1996, Pages 275-282

  Saegusa, Makoto ^a   Kamata, Yoko ^a   Isono, Masako ^a   Okayasu, Isao ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bcl 2; Endometrial carcinoma; ER; PR

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

APOPTOSIS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MITOTIC INDEX; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0029835824     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199611)180:3<275::AID-PATH660>3.0.CO;2-A     Document Type: Article

References (31)

1. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995; 76: 2034-2040.
2. Creasman WT, McCarty KS Sr, Barton TK, McCarty KS Jr. Clinical correlates of estrogen- and progesterone-binding proteins in human endometrial adenocarcinomas. Obstet Gynecol 1980; 55: 363-370.
3. Ehrlich CE, Young PCM, Cleary RE. Cytoplasmic progesterone receptors in normal, hyperplastic, and carcinomatous endometrium: therapeutic implications. Am J Obstet Gynecol 1981; 141: 539-546.
4. Martin JD, Hahnel R, McCartney AJ, Woodings TL. The effect of estrogen receptor status on survival in patients with endometrial carcinoma. Am J Obstet Gynecol 1983; 147: 322-324.
5. Gompel A, Sabourin JC, Martin A, et al. Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 1994; 144: 1195-1202.
6. Chan WK, Mole MM, Levison DA, et al. Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol 1995; 177; 241-246.
7. Saegusa M, Takano Y, Wakabayashi T, Okayasu I. Apoptosis in gastric carcinomas and its association with cell proliferation and differentiation. Jpn J Cancer Res 1995; 86: 743-748.
8. Shoji Y, Saegusa M, Takano Y, Ohbu M, Okayasu I. Correlation of apoptosis with tumour cell differentiation, progression and HPV infection in cervical carcinoma. J Clin Pathol 1996; 49: 134-138.
9. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
10. Creasman WT. Announcement, FIGO stages: 1988 revisions. Gynecol Oncol 1989; 35: 125-127.
11. Sinicrope FA, Ruan SB, Cleary KR, et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Rex 1995; 55: 237-241.
12. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026.
13. Creasman WT, Soper JT, McCarty KLS Jr, et al. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 1985; 151: 922-932.
14. Bhargava V, Kell D, van de Rijn M, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994; 145: 535-540.
15. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence ofandrogen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
16. Otsuki Y, Misaki O, Sugimoto O, et al. Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle. Lancet 1994; 344: 28-29.
17. Press MF, Udove JA, Greene GL. Progesterone receptor distribution in the human endometrium: analysis using monoclonal antibodies to the human progesterone receptor. Am J Pathol 1988; 131: 112-124.
18. Benito A, Grillot D, Nunez G, Fernandez-Luna JL. Regulation and function of bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am J Pathol 1995; 146: 481-490.
19. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985; 56: 1452-1455.
20. Tomei LD, Kanter P, Wenner CE. Inhibition of radiation-induced apoptosis in vitro by tumour promoters. Biochem Biophys Res Commun 1988; 155: 324-331.
21. Soper JT, Segreti EM, Novotny DB, et al. Estrogen and progesterone receptor content of endometrial carcinomas: comparison of total tissue versus cancer component analysis. Gynecol Oncol 1990; 36: 363-368.
22. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993; 71: 1467-1470.
23. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145: 1191-1198.
24. Lipponen P, Pietilainen T, Kosma V-M, et al Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995; 177: 49-55.
25. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
26. Allan DJ, Harmon BV, Kerr JFR. Cell death in spermatogenesis. In: Potten CS, ed. Perspectives on Mammalian Cell Death. Oxford: Oxford University Press, 1987; 229-258.
27. Ijiri K, Potten CS. Cell death in cell hierarchies in adult mammalian tissues. In: Potten CS, ed. Perspectives in Mammalian Cell Death. Oxford: Oxford University Press, 1987; 327-356.
28. Walker NI, Bennett RE, Kerr JFR. Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anal 1989; 185: 19-32.
29. Aihara M, Truong LD, Dunn JK, et al. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994; 25: 797-801.
30. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 1993; 82: 15-21.
31. Hollowood K, Macartney JC. Reduced apoptolic cell death in follicular lymphoma. J Pathol 1991; 163: 337-342.